Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Cara Therapeutics has been trending all over the internet after the company recently decided to explore a potential sale.</li><li>Recent, Cara Therapeutics' management announced a focus shift toward its most promising project, oral difelikefalin for treating notalgia paresthetica (NP), a chronic neuropathic condition with no currently approved therapies.</li><li>The reallocation of resources toward this program enables Cara Therapeutics to extend its cash runway into 2026, potentially covering all crucial value inflection milestones for the NP program.</li></ul>

Cara Therapeutics has been trending all over the internet after the company recently decided to explore a potential sale.Recent, Cara Therapeutics' management announced a focus shift toward its most promising project, oral difelikefalin for treating notalgia paresthetica (NP), a chronic neuropathic condition with no currently approved therapies.The reallocation of resources toward this program enables Cara Therapeutics to extend its cash runway into 2026, potentially covering all crucial value inflection milestones for the NP program.

Cara Therapeutics Exploring A Potential Sale But Can It Really Get Acquired? - Financial Forecasts

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<p>As the broad market takes a breather, the weight of the evidence continues to support our belief that we are in the early stages of a broad-based advance. As long as there are no significant negative market developments, a buy-the-dip mentality is warranted. In today’s report we highlight attractive Groups and stocks within Consumer Discretionary, Health Care, and Transportation: Hotels &amp; Resorts, Large/Mid-Cap, Hospitals, and Vehicle Rentals/Leasing.</p>

As the broad market takes a breather, the weight of the evidence continues to support our belief that we are in the early stages of a broad-based advance. As long as there are no significant negative market developments, a buy-the-dip mentality is warranted. In today’s report we highlight attractive Groups and stocks within Consumer Discretionary, Health Care, and Transportation: Hotels &amp; Resorts, Large/Mid-Cap, Hospitals, and Vehicle Rentals/Leasing.

United States

Calithera Biosciences, Inc. provides pharmaceutical products. The Company is focused on discovering and developing novel small molecule drugs against tumor metabolism and immunology for the treatment of cancer. Calithera Biosciences serves patrients in the United States.

Aspira Women's Health Inc. operates as a biotech company. The Company develops and discovers testing and treatments for gynecologic issues. Aspira Women's Health serves customers in the State of Texas.

Minerva Neurosciences, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops new therapies to treat central nervous system (CNS) and neuropsychiatric diseases. Minerva Neurosciences serves communities in the United States.

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company produces differentiated drugs that helps patients suffering from cancer, severe asthma, anemia, and other medical conditions. Pieris Pharmaceuticals serves customers worldwide.

KALA BIO, Inc. operates as a clinical-stage biopharmaceutical company. The Company designs and develops proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts, and the female reproductive systems. KALA BIO markets its products worldwide.

Calyxt, Inc. provides agricultural biotechnology services. The Company researches and develops seeds and food ingredients for agricultural, feed, and food applications, as well as offers fat saturation and gluten reduction in soybean oil and wheat. Calyxt markets its products in the United States.

Evelo Biosciences, Inc. operates as a bio-technology company. The Company develops therapies for the treatment of the gut-body network. Evelo Biosciences also offers treatment for cancer and inflammatory diseases. Evelo Biosciences serves customers in the State of Massachusetts.

UNITY Biotechnology, Inc. operates as a biotechnology company. The Company develops therapeutics that prevents, halts, and reverses osteoarthritis, ophthalmology, and pulmonary diseases. UNITY Biotechnology serves the health care sectors in the United States.

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic, and infectious diseases.

vTv Therapeutics Inc. operates as a clinical-stage pharmaceutical company. The Company focuses on the discovery and development of human therapeutics to fill unmet medical needs. vTv Therapeutics serves customers in the United States.

Biotron Limited specializes in the funding, management and commercialization of biomedical projects that result from research conducted at the John Curtin School of Medical Research, a research institute within the Australian National University.  The Group conducts diagnostic and therapeutic research with the intention of creating compounds and diagnostics that can be sold or licensed.

Immuron Limited operates as a biopharmaceutical company. The Company focuses on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron's technology platform is developing and producing an orally stable therapeutic for various immune mediated and inflammatory disorders.

Alterity Therapeutics Limited operates as a biotechnology company. The Company researches and develops therapeutic drugs used for treatment of alzheimer's diseases and age related disorders. Alterity Therapeutics serves patients in Australia.

D.Western Therapeutics Institute Inc.(DWTI) is a biotechnology (bio-venture) company that focuses on development of new drugs. The Company's focus is on protein kinase inhibitors. DWTI discovers and develops several drugs, such as antiglaucoma, antihypertensive, neuroprotective, antithrombogenic, antiatherosclerosis and anticancer.

D.Western Therapeutics Institute Inc. (4576 JP)

TRANS GENIC INC. develops, produces, and sells specific idiotype bearing antibody (bio reagent).  The Company also develops mutant mice and sells mice' genetic function analysis data.

Ribomic, Inc. develops ribonucleic acids (RNA) called aptamers. The company conduct research and develops new medication based on Ribomic Aptamer Refined Th erapeutics System. The company also conduct advisory to pharmaceutical companies and product licensing.

Prescient Therapeutics Limited is an oncology company. The Company researches, develop, and commercializes novel cancer treatments treatments. Prescient Therapeutics treats myeloma, breast, and pancreatic cancer.

Bharat Immunologicals & Biologicals Corporation Ltd. manufactures and distributes pharmaceutical drugs and vaccines. The Company's primary product is oral polio vaccine (OPV).

Vectorite Biotech Inc. is a biomedical company focused on the research and development of adult healthy cells and cell formulation, medical technologies and product development of targeted immune cell therapy treatment to treat disease and improve the patients' quality of life.

OptiBiotix Health plc, a life sciences company, engages in the research and development of microbiome modulators in the United Kingdom. The company has a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest, and appetite suppression. Its products under development include novel microbial strains for cholesterol and lipid management; an ingredient formulation, which is scientifically formulated to support and maintain weight loss; and microbiome modulators that enhance the growth of specific microbial species in the human microbiome. The company is based in York, the United Kingdom.

Cara Therapeutics, Inc. develops therapeutics. The Company offers novel drugs for the treatment of human diseases associated with pain and inflammation. Cara Therapeutics serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cara Therapeutics (CARA US)

Cara Therapeutics Exploring A Potential Sale But Can It Really Get Acquired? - Financial Forecasts

Cara Therapeutics has been trending all over the internet after the company recently decided to explore a potential sale. Recent, Cara...

Baptista Research

U.S. Equity Strategy: Taking a Breather

As the broad market takes a breather, the weight of the evidence continues to support our belief that we are in the early stages of a broad-based...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)